PRESS RELEASES

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
Olga Rosenman Olga Rosenman

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025.

CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference

Recent SEPA Funding Enhances Operational Flexibility

Last week, Scinai raised $1.38 million in gross proceeds through drawdowns under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The funding was executed at a volume-weighted average price of approximately $3.03 per ADS, reflecting a 3% discount to market, and was completed without any warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai's balance sheet and provide additional capital to advance both its CDMO growth and R&D programs. The company is now accelerating supplier and partner engagements in order to advance its nanobody pipeline toward IND-enabling studies, while simultaneously working to expand CDMO capacity and marketing outreach.

CDMO Business Scales Rapidly; 2025 Revenue Expected to Reach $2M

Scinai's Q1 2025 financial results, released last month, showed rapid growth in CDMO revenues, nearly matching full-year 2024 revenues in just the first quarter. Based on strong demand and capacity utilization, the company has issued 2025 revenue guidance of approximately $2 million. Scinai currently anticipates its CDMO unit will reach breakeven by end of 2026, with long-term revenue potential of $12 million annually under a single production shift, scalable further with additional shifts.

Read More
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
Alona Tal Alona Tal

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn. Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company’s CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on May 7, 2025, CDMO revenues for the full year 2024 were $658 thousand. The year-over-year increase in revenues for the first quarter of 2025 reflects a higher number of contracts executed during the period, driven by continued growth in the CDMO business.

Read More
Scinai Leadership to Showcase Company’s cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
Olga Rosenman Olga Rosenman

Scinai Leadership to Showcase Company’s cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.

Scinai’s CEO, Mr. Amir Reichman, and CTO, Dr. Dalit Weinstein-Fischer will be holding meetings during the conference days with:

·         Prospective clients of the company’s end-to-end biologics CDMO services.

·         Potential pharma partners in the field of I&I interested in co-developing or in-licensing one of Scinai’s innovative NanoAbs.

·         Potential pharma partners in the field of dermatology interested in Scinai’s drug development program for local treatment of mild to moderate plaque psoriasis – “the Botox-like solution for psoriatic patients”

·         Institutional and private investors interested in SCNI’s value proposition.

Read More